Visa Posts 13% Revenue Rise and Lifts Dividend 16%

Visa grew fiscal fourth-quarter revenue 13% and raised its quarterly dividend 16%, the payments network reported on October 27. Adjusted earnings beat the $3.44 consensus estimate cited by Benzinga. Yet the share price fell 1.71% to $395 in extended trading, according to the publication's 4:30 p.m. Eastern report. A beat, in other words, did not buy applause.

What did the quarter deliver?

Revenue reached $12.14 billion against a $12.08 billion consensus — a margin of roughly $60 million, thin enough that the "beat" deserves an asterisk. The operating drivers underneath were firmer:

• Payments volume grew 9% on a constant-dollar basis.
• Cross-border volume excluding intra-Europe transactions climbed 14%.
• Processed transactions rose 10% to 74.2 billion.

The full fiscal year carried the same shape. Net revenue came in at $45.9 billion, up 15%. Non-GAAP earnings reached $13.27 per share, up 16%. The board lifted the quarterly cash dividend to $0.780 per share. Growth is broad, steady and unglamorous; nothing in the release suggests acceleration beyond the prior year's pace, and the company said nothing about the drivers behind the after-hours decline. The dividend raise, at 16%, is the loudest signal of confidence in the numbers.

Why is Visa paying $2.4 billion for BioCatch?

The earnings release sits beside a larger strategic bet. On August 3, Visa announced an agreement to acquire BioCatch from funds advised by Permira and other shareholders for $2.4 billion in cash. BioCatch analyzes behavioral, device and network signals to separate legitimate users from fraudsters.

Visa said the technology would complement its existing security products by helping clients detect account takeovers, scams, money mules and application fraud. The target is not a novice: BioCatch served more than 350 banking clients in 21 countries at the time of the announcement. In the same statement, Visa said it had invested more than $13 billion in technology and infrastructure over the preceding five years to safeguard payments.

Read the claims carefully. A $2.4 billion cash outlay against a claimed $13 billion cumulative security spend frames the deal as incremental, not transformative. The transaction remains subject to customary closing conditions and applicable regulatory approvals, with completion expected by the end of Visa's fiscal second quarter of 2027 — a window long enough for regulators or counterparties to reshape terms. Visa did not disclose BioCatch's revenue, profitability or the multiple it is paying, and those omissions are the ones a skeptic keeps.

What should finance chiefs watch next?

Three figures anchor the forward view: the 14% cross-border volume growth, which signals sustained international card activity; the 74.2 billion processed transactions, which measures the network's throughput directly; and the fiscal 2027 closing deadline for BioCatch, which will test whether the fraud-prevention expansion survives regulatory review intact.

The dividend of $0.780 per share per quarter converts the earnings story into cash returned to shareholders — a commitment the board has now made regardless of after-hours sentiment. The share price fell on the day the numbers rose; the market discounted what the release did not say about future growth.

The plain takeaway: Visa printed strong volumes and returned more cash, but the market priced in questions the company did not answer.